Log in
Enquire now
AN2

AN2

AN2 is a novel medicines targeting infectious diseases founded by Eric Easom.

OverviewStructured DataIssuesContributors

Contents

an2therapeutics.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Biopharmaceutical
Biopharmaceutical
Location
San Francisco
San Francisco
Menlo Park, California
Menlo Park, California
CEO
‌
Eric Easom
0
Founder
‌
Eric Easom
0
Pitchbook URL
pitchbook.com/profiles...343121-05
Legal Name
AN2 Therapeutics, Inc.
Number of Employees (Ranges)
11 – 50
Email Address
info@an2therapeutics.com
Phone Number
+16503319090
Full Address
1800 El Camino Real, Suite D Menlo Park, CA 94027, USA
Investors
Hatteras Venture Partners
Hatteras Venture Partners
BioRock Ventures
BioRock Ventures
Adjuvant Capital
Adjuvant Capital
Brii Biosciences
Brii Biosciences
Surveyor Capital
Surveyor Capital
RA Capital Management
RA Capital Management
Total Funding Amount (USD)
92,000,000
Latest Funding Round Date
January 7, 2022
Exchange
Nasdaq
Nasdaq
Latest Funding Type
Series B
Series B

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
80,000,000
Ticker Symbol
ANTX
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like AN2

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.